Actelion to start Phase III studies into cadazolid for C. difficile related diarrhea

11 September 2013

Swiss biotech firm Actelion (SIX: ATLN) will initiate a Phase III clinical development program to assess the efficacy and safety of cadazolid in patients with Clostridium difficile-associated diarrhea (CDAD).

The Phase III program will consist of two identical multicenter, randomized, double-blind studies comparing the efficacy and safety of cadazolid (250mg administered orally twice daily for 10 days) versus vancomycin (125mg administered orally four times daily for 10 days). The program is expected to enroll more than 1,250 patients worldwide, and is planned to start before the end of the year.

Phase II results positive

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK